1. Supporting Patient-Centric Clinical Trials from Point-of-Origin through the Last Mile

    Wes Wheeler, CEO of Marken explains how Direct-to-Patient (DTP) clinical trials are becoming an industry standard.

  2. Addressing Development Challenges for Complex Biologic Drug Candidates

    Karen Fallen, Vice President, Business Unit Head of Clinical Development & Manufacturing at Lonza, discusses how to handle increasingly complex biological candidates.

  3. Inside Mergers & Acquisitions

    Kevin Bottomley, Partner, Results Healthcare discusses the fundamentals of M&A activity in pharma. 

  4. Tackling Powder Flow Problems by Choosing the Right Equipment

    Identifying the source of product flow problems and correcting them with the right piece of equipment will result in more efficient and quality manufacturing, says Matt Hicks , Chief Operating Officer & Counsel for Federal Equipment Company.

  5. Flexible, Mobile, Modular: High-Containment Viral Vector Center of Excellence

    Next-generation viral vector and gene therapy manufacturing facilities must be flexible, says Thomas Page, Ph.D., Vice President of Engineering and Asset Development for Fujifilm Diosynth Biotechnologies.

  6. Establishing Specialized CDMO Capabilities for the Production of Advanced Therapies
    Oliver Technow, President of BioVectra, explains the necessity of forward-thinking CDMOs.
  7. Allergan and Molecular Partners Announce Two Positive Phase 3 Clinical Trials

    Two pivotal head-to-head trials demonstrate the efficacy of Abicipar 12-week fixed dosing regimen with 50 percent fewer injections versus ranibizumab.


  8. New Nature Medicine Study Demonstrates Ability of The Guardant360 Assay to Predict Patient Response to Immunotherapy in Advanced Gastric Cancer Patients

    Researchers from Samsung Medical Center and Guardant Health, Inc. have demonstrated the feasibility of determining a measure analogous to tumor mutation burden (TMB), a promising biomarker that may predict patient response to certain immunotherapies, utilizing the Guardant360® assay, a comprehensive liquid biopsy.

  9. Xtandi Gets FDA Second Cancer Therapy Approval

    Drug from Pfizer and Astellas will compete with J&J’s Erleada as a treatment for early-stage prostate cancer.

  10. China Turning to Indian Drug Manufacturers in Response to Trade War with US

    Talks are underway to open China’s market to Indian drugs.

  11. Reducing Time to Market with Targeted Regulatory Affairs Support

    Regulatory affairs activities are essential components of any drug development and commercialization program, explains Maryse Phan, Head of Regulatory Affairs for API Manufacturing, Servier CDMO.

  12. Five Tips to Ensure Faster Equipment Procurement and Installation
    Used equipment is readily available, cuts lead time for delivery and install, and allows faster product launch, says Jim Coyne, Business Development/Sales at Federal Equipment Company.
  13. WuXi Laboratory Testing Division: Propelling Innovation and Better Treatments for Patients

    Jason Liu, Ph.D., MBA, SVP of WuXi AppTec and COO of Laboratory Testing Division and Francis L. Tse, Ph.D., VP of WuXi AppTec and CSO / Head of US Sites of the Laboratory Testing Division describe how WuXi AppTec’s Laboratory Testing Division (LTD) has expanded its global footprint.

  14. Challenges for Next-Generation Biological Therapeutics Discovery and Development

    In the coming years, novel biological therapeutics will continue to enrich our medicinal arsenal for serious diseases and address unmet medical needs. 

  15. Thinking a Generation Ahead: Biologics-Based Therapy

    The next generation of drug development and manufacturing may take many forms: from a transformation in the way facilities are structured, to a reliance on continuous manufacturing, to embedding 3D printing systems into operations and incorporating flexibility into design. 

  16. Finishing Touches – The Future of Fill-Finish and Pharma Packaging
    Fill-finish operations must evolve in order to get more effective medicine to market in a timely manner, reliably and efficiently. 
  17. Locus Biosciences Acquires EpiBiome's High-Throughput Discovery Platform to Enhance its Global Leadership in CRISPR-Engineered Phage Therapeutics

    Acquisition significantly accelerates development of new products targeting antibiotic-resistant pathogens and microbiome indications.

  18. Appeals Board Rules in Favor of Novartis and its Multiple Sclerosis Drug Gilenya
    Novartis has extended its exclusivity on Gilenya from 2019 to 2027. 
  19. Vyriad Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer

    The collaboration agreement with will expand its ongoing Phase 1 clinical trial program in solid tumors to include a combination study of its lead asset, Voyager-V1, with avelumab, a human anti-PD-L1 antibody. 

  20. Safety Concerns Raised about Valsartan from China

    The common blood-pressure medication valsartan supplied by Chinese manufacturer Zhejiang Huahai Pharmaceutical (ZHP) is now subject to recalls in both the US and Europe. 

View All

Road To BIO: Coming Soon To Your Screen Q4 2018
The Road to BIO in Review
The Road To BIO: Day 12 California
The Road To BIO: Day 11 Arizona /// California
The Road To BIO: Day 10 Texas /// Arizona
The Road To BIO: Day 9 Texas
The Road To BIO: Day 8 Texas
The Road To BIO: Day 7 Mississippi /// Texas
The Road To BIO: Day 6 Georgia /// Mississippi
The Road To BIO: Day 5 South Carolina /// Georgia
The Road To BIO: Day 4 Tennessee /// South Carolina
The Road To BIO: Day 3 Pennsylvania /// Tennessee
The Road To BIO: Day 2 New York /// Pennsylvania
For Your Listening Pleasure
The full story of this epic journey can be experienced as an audiobook. Listen to the story behind the story – the characters, the challenges, and all 12 days of the Road To BIO.
Nice Insight Awareness/Perception Scorecard

Research. Compare. Contact. Find the Ideal Partner.

Customer Awareness (CA) describes a buyer’s knowledge of your offering, while Customer Perception (CP) describes how a buyer rates your company based on that knowledge. Nice Insight’s CA/CP scorecard allows you to measure market awareness and perception of you and your industry peers based on acknowledged outsourcing drivers.

  1. Search by company type, region, market segment and services.
  2. Select up to 5 companies to compare.
  3. View CA & CP performance scores against industry benchmark ratings.
Drug Development

Appeals Board Rules in Favor of Novartis and its Multiple Sclerosis Drug Gilenya

Jul 18, 2018 11:52:08 AM PAO-M07-18-NI-014

Safety Concerns Raised about Valsartan from China

Jul 18, 2018 11:46:26 AM PAO-M07-18-NI-013
FDA Approval

Xtandi Gets FDA Second Cancer Therapy Approval

Jul 18, 2018 11:42:55 AM PAO-M07-18-NI-012
Industry Trend

China Turning to Indian Drug Manufacturers in Response to Trade War with US

Jul 18, 2018 11:35:35 AM PAO-M07-18-NI-011

FDA Committee Gives Nod to New Treatment for Plasmodium Vivax Malaria

Jul 17, 2018 2:16:02 PM PAO-M07-18-NI-010
Drug Development

New Antibiotic to be Tested against Potential Bioweapons

Jul 17, 2018 2:12:46 PM PAO-M07-18-NI-009

Digital Ad Spending by Pharma is Growing Slowly

Jul 13, 2018 11:40:21 AM PAO-M07-18-NI-008
FDA Approval

New Treatment for Excessive Sweating Gets FDA Approval

Jul 13, 2018 11:29:42 AM PAO-M07-18-NI-008

Women’s Health Company to Expand

Jul 13, 2018 11:25:25 AM PAO-M07-18-NI-007
Clinical Research

Eating Well Might Improve Cancer Treatments

Jul 12, 2018 2:59:14 PM PAO-M07-18-NI-006

Organ-on-a-Chip Company Raises $36 Million

Jul 12, 2018 2:54:35 PM PAO-M07-18-NI-005

Bosch Packaging Business Up for Sale

Jul 10, 2018 11:06:51 AM PAO-M07-18-NI-004

Gottlieb Discusses Results of Online Opioid Summit

Jul 10, 2018 11:04:07 AM PAO-M07-18-NI-003

Alcon Set Out On its Own

Jul 10, 2018 10:59:59 AM PAO-M07-18-NI-002

Japan Approves Two New AstraZeneca Cancer Meds

Jul 10, 2018 10:24:44 AM PAO-M07-18-NI-001

Nice Insight Overview

Changes in the  Biopharma Industry: from Minor to Major Evolution
New technologies such as gene editing are leading to the development of even more advanced, targeted medicines.

The Next-Generation Player

Addressing Development Challenges for Complex Biologic Drug Candidates
At Lonza, we are constantly looking to reduce the development timeline, giving our customers more control over their projects.

Karen Fallen, Vice President, Business Unit Head of Clinical Development & Manufacturing Lonza Pharma & Biotech

M+A Column

Inside Mergers & Acquisitions
Kevin Bottomley Partner, Results Healthcare
Deals in the pharmaceutical industry are an important mechanism of acquiring innovation, business and efficiency.

Nice Insight Overview

Doping: Famous Cases, Substances and Values in Sports

Marc Technow, Nice Insight